Literature DB >> 19707183

Cardiovascular pharmacogenomics and individualized drug therapy.

Naveen L Pereira1, Richard M Weinshilboum.   

Abstract

The goal of individualized drug therapy requires physicians to be able to accurately predict an individual's response to a drug. Both genetic and environmental factors are known to influence drug response. 'Pharmacogenetics' is the study of the role of inheritance in variation in drug response phenotypes. Pharmacogenetics is now moving genome-wide to become 'pharmacogenomics', resulting in the recognition of novel biomarkers for individual variation in drug response. This article reviews the development, promise and challenges facing pharmacogenomics, using examples of drugs used to treat or prevent cardiovascular disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19707183      PMCID： PMC3108370          DOI： 10.1038/nrcardio.2009.154

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  41 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Warfarin pharmacogenetics: economic considerations.

Authors:  Dyfrig A Hughes; Munir Pirmohamed
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 3.  Pharmacogenomics of statin response.

Authors:  Lara M Mangravite; Ronald M Krauss
Journal:  Curr Opin Lipidol       Date:  2007-08       Impact factor: 4.776

Review 4.  The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.

Authors:  L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2008-09       Impact factor: 6.875

5.  Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008.

Authors:  Kathy L Hudson; M K Holohan; Francis S Collins
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

6.  A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors.

Authors:  K M Small; S L Forbes; F F Rahman; K M Bridges; S B Liggett
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

Authors:  E Aklillu; I Persson; L Bertilsson; I Johansson; F Rodrigues; M Ingelman-Sundberg
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

8.  Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

Authors:  Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

9.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

10.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

Authors:  F J Gonzalez; F Vilbois; J P Hardwick; O W McBride; D W Nebert; H V Gelboin; U A Meyer
Journal:  Genomics       Date:  1988-02       Impact factor: 5.736
View more
  19 in total

Review 1.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

2.  Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.

Authors:  Nimer Alkhatib; Nancy K Sweitzer; Christopher S Lee; Brian Erstad; Marion Slack; Mahdi Gharaibeh; Jason Karnes; Walter Klimecki; Kenneth Ramos; Ivo Abraham
Journal:  Am J Cardiovasc Drugs       Date:  2021-03       Impact factor: 3.571

Review 3.  Ten questions about systems biology.

Authors:  Michael J Joyner; Bente K Pedersen
Journal:  J Physiol       Date:  2011-01-04       Impact factor: 5.182

Review 4.  Genetics of dilated cardiomyopathy: practical implications for heart failure management.

Authors:  Andrew N Rosenbaum; Katherine E Agre; Naveen L Pereira
Journal:  Nat Rev Cardiol       Date:  2019-10-11       Impact factor: 32.419

Review 5.  Genotype-based clinical trials in cardiovascular disease.

Authors:  Naveen L Pereira; Daniel J Sargent; Michael E Farkouh; Charanjit S Rihal
Journal:  Nat Rev Cardiol       Date:  2015-05-05       Impact factor: 32.419

Review 6.  Exercise training response heterogeneity: physiological and molecular insights.

Authors:  Lauren M Sparks
Journal:  Diabetologia       Date:  2017-10-14       Impact factor: 10.122

Review 7.  Pharmacogenetics of heart failure.

Authors:  Luisa Mestroni; Rene L Begay; Sharon L Graw; Matthew R G Taylor
Journal:  Curr Opin Cardiol       Date:  2014-05       Impact factor: 2.161

8.  Genetic Risk and Altering Lipids With Lifestyle Changes and Metformin: Is Fate Modifiable?

Authors:  Naveen L Pereira
Journal:  Circ Cardiovasc Genet       Date:  2016-12

Review 9.  Genetics of atrial fibrillation: implications for future research directions and personalized medicine.

Authors:  Steven A Lubitz; Cevher Ozcan; Jared W Magnani; Stefan Kääb; Emelia J Benjamin; Patrick T Ellinor
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-06

10.  Clopidogrel Pharmacogenetics.

Authors:  Naveen L Pereira; Charanjit S Rihal; Derek Y F So; Yves Rosenberg; Ryan J Lennon; Verghese Mathew; Shaun G Goodman; Richard M Weinshilboum; Liewei Wang; Linnea M Baudhuin; Amir Lerman; Ahmed Hasan; Erin Iturriaga; Yi-Ping Fu; Nancy Geller; Kent Bailey; Michael E Farkouh
Journal:  Circ Cardiovasc Interv       Date:  2019-04       Impact factor: 6.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.